NCT01494584View on ClinicalTrials.gov

Study in Pediatric Subjects With Epilepsy

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 25, 2012

Primary Completion Date

April 29, 2013

Study Completion Date

April 29, 2013

Conditions
Epilepsy
Interventions
DRUG

ezogabine/retigabine

ezogabine dose escalation

Trial Locations (4)

33414

GSK Investigational Site, Wellington

38105

GSK Investigational Site, Memphis

90027

GSK Investigational Site, Los Angeles

75230-2507

GSK Investigational Site, Dallas

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT01494584 - Study in Pediatric Subjects With Epilepsy | Biotech Hunter | Biotech Hunter